Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY17.73
+0.24 (+1.37%)
CN SHZ Healthcare Biotechnology
Address
No. 2, Yuli Industrial Zone 333000
Jingdezhen, CN
Jingdezhen, CN
CEO
Jian Hua Bao
Website
fushine.cn
IPO
2015-12-22
ISIN CNE1000024Z7
Description
Jiangxi Fushine Pharmaceutical Co., Ltd. is engaged in the global research, development, production, and marketing of active pharmaceutical ingredients (APIs) and key chemical compounds for drug synthesis. Its product portfolio includes important antibiotics like penicillin and carbapenem, alongside a variety of other pharmaceutical offerings. The company also extends its expertise by providing contract research, development, and manufacturing services. Founded in 2002 and headquartered in Jingdezhen, China, the firm was initially named Jingdezhen Fuxiang Pharmaceutical Co., Ltd. before adopting its current designation in August 2012.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY17.73
+0.24 (+1.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
49M
Beta
0.28
Float Shares
490.89M
Free Float %
91.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.29% | -4.67% | -20.81% | -6.25% | -5.44% | +1.26% | +60.38% | +20.19% | +22.11% | -9.95% | +299.48% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17.73
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.36
Grey zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+0.6% Q1'26: +53.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+80.4% ★ Q1'26: +2,650.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-17.0% Q1'26: -9.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1.6% Q1'26: +20.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-0.6% ★ Q1'26: +8.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.5% ★ Q1'26: -4.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×8.19× Q1'26: 5.42× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
579.74M
est: 582.50M (-0.5%)
|
763.69M
est: 706.00M (+8.2%)
|
958.15M
est: 849.00M (+12.9%)
|
1.16B
est: 1.16B (+0.0%)
|
1.35B
est: 1.42B (-4.6%)
|
1.49B
est: 1.67B (-10.5%)
|
1.65B
est.
|
1.43B
est: 1.75B (-18.3%)
|
1.65B
est: 2.13B (-22.5%)
|
1.61B
est: 2.13B (-24.3%)
|
1.18B
est: 1.51B (-22.0%)
|
1.18B
est: 1.15B (+2.9%)
|
1.49B
1.49B – 1.49B
+29.2% YoY
|
1.64B
1.64B – 1.64B
+9.9% YoY
|
| EBITDA |
152.30M
est: 43.18M (+252.7%)
|
246.38M
est: 52.34M (+370.8%)
|
262.02M
est: 62.94M (+316.3%)
|
304.38M
est: 86.22M (+253.0%)
|
459.86M
est: 105.27M (+336.8%)
|
477.33M
est: 123.60M (+286.2%)
|
121.95M
est.
|
179.47M
est: 129.78M (+38.3%)
|
23.02M
est: 157.61M (-85.4%)
|
-31.68M
est: 157.61M (-120.1%)
|
-76.34M
est: 59.58M (-228.1%)
|
168.59M
est: 45.46M (+270.9%)
|
58.71M
58.71M – 58.71M
+29.2% YoY
|
64.51M
64.51M – 64.51M
+9.9% YoY
|
| EBIT |
123.80M
est: -7.66M (+1,715.6%)
|
212.21M
est: -9.29M (+2,385.0%)
|
216.82M
est: -11.17M (+2,041.4%)
|
251.55M
est: -15.30M (+1,744.2%)
|
393.33M
est: -18.68M (+2,205.7%)
|
403.39M
est: -21.93M (+1,939.3%)
|
-21.64M
est.
|
80.91M
est: -23.03M (+451.3%)
|
-100.82M
est: -27.97M (-260.5%)
|
-191.14M
est: -27.97M (-583.5%)
|
-247.06M
est: -105.43M (-134.3%)
|
-18.97M
est: -80.44M (+76.4%)
|
-103.90M
-103.90M – -103.90M
-29.2% YoY
|
-114.16M
-114.16M – -114.16M
-9.9% YoY
|
| Net Income |
93.60M
est: 103.42M (-9.5%)
|
173.91M
est: 146.63M (+18.6%)
|
177.55M
est: 166.73M (+6.5%)
|
194.72M
est: 241.76M (-19.5%)
|
305.84M
est: 383.48M (-20.2%)
|
319.30M
est: 458.84M (-30.4%)
|
330.79M
est.
|
48.83M
est: 69.36M (-29.6%)
|
-141.47M
est: 282.77M (-150.0%)
|
-200.80M
est: 282.77M (-171.0%)
|
-272.10M
est: -21.23M (-1,181.9%)
|
-55.03M
est: -58.37M (+5.7%)
|
191.04M
191.04M – 191.04M
+427.3% YoY
|
233.50M
233.50M – 233.50M
+22.2% YoY
|
| SGA |
79.78M
est: 26.71M (+198.7%)
|
133.75M
est: 32.37M (+313.2%)
|
100.96M
est: 38.93M (+159.4%)
|
111.39M
est: 53.32M (+108.9%)
|
120.63M
est: 65.11M (+85.3%)
|
121.47M
est: 76.44M (+58.9%)
|
75.42M
est.
|
163.47M
est: 80.27M (+103.7%)
|
179.91M
est: 97.48M (+84.6%)
|
193.55M
est: 97.48M (+98.6%)
|
152.90M
est: 159.03M (-3.9%)
|
62.78M
est: 121.33M (-48.3%)
|
156.72M
156.72M – 156.72M
+29.2% YoY
|
172.20M
172.20M – 172.20M
+9.9% YoY
|
| EPS |
0.30
est: 0.19 (+54.8%)
|
0.42
est: 0.27 (+52.8%)
|
0.42
est: 0.31 (+34.4%)
|
0.46
est: 0.45 (+1.5%)
|
0.71
est: 0.72 (-1.2%)
|
0.70
est: 0.86 (-18.6%)
|
0.62
est.
|
0.09
est: 0.13 (-30.8%)
|
-0.26
est: 0.53 (-149.1%)
|
-0.37
est: 0.53 (-169.8%)
|
-0.51
est: -0.04 (-1,175.0%)
|
-0.10
est: -0.11 (+9.1%)
|
0.36
0.36 – 0.36
+427.3% YoY
|
0.44
0.44 – 0.44
+22.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-393.21M
OE per share TTM
-0.61
Owner's Yield
-4.79%
Maintenance CapEx ratio
182.46%
Maint CapEx / Avg PPE
132.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 3 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 86.6K | 0.29% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 86.1K | 0.28% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 64.1K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-9.7K
Shares Outstanding
538.65M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guang Yang | Financial Director | — | male |
| Haipeng Wei | Deputy General Manager | — | male |
| Haiyan Xie | Accounting Supervisor | — | — |
| Jian Hua Bao | GM & Chairman | — | male |
| Wei Dong | Manager of the Sales Department & Supervisor | — | male |
| Xiang Ming Zhang | Deputy General Manager | — | male |
| Ying Liu | Deputy General Manager | — | female |
| Yinghui Chen | Deputy General Manager | — | male |
| Yun Peng | Deputy GM & Secretary of the Board of Directors | — | female |
| Zhen Liang Dai | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300497.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
